Figure 1

Kaplan–Meier overall (n=1181) and progression-free survival (n=660) estimates for patients with newly diagnosed multiple myeloma stratified by the number of cytogenetic high-risk abnormalities (HRA): (a,c) established HRA only, (b,d) considering monosomy 13 as an additional HRA.